Results 61 to 70 of about 23,672 (222)

JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison

open access: yesCancer Medicine, Volume 14, Issue 22, November 2025.
ABSTRACT Background Giant cell tumors of bone (GCTB) are RANK/RANK‐ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients. A single‐arm, phase II study demonstrated the promising efficacy of JMT103 in unresectable or surgically challenging GCTB.
Hairong Xu   +18 more
wiley   +1 more source

NEOPLASMS IN ACROMEGALY

open access: yesAlʹmanah Kliničeskoj Mediciny, 2017
Acromegaly is a  rare disease with increased growth hormone secretion most often caused by pituitary adenoma. Not adequately treated acromegaly may lead to early death related to increased rates of acute cardiovascular events, sleep apnea, metabolic ...
I. D. Chikh   +3 more
doaj   +1 more source

Acromegaly and hypertension [PDF]

open access: yesJichu yixue yu linchuang, 2021
Acromegaly is usually caused by pituitary adenomas that secrete growth hormone (GH). The disease is prone to be complicated with hypertension and thus aggravates the state of the illness and increase the disease burden.
WANG Shu-chang, ZHU Hui-juan, PAN Hui
doaj  

BACKGROUND CHANGES OF THE DIGESTIVE SYSTEM MUCOSA IN PATIENTS WITH ACROMEGALY

open access: yesAlʹmanah Kliničeskoj Mediciny, 2016
Background: Gastrointestinal tract lesions due to the growth hormone impact on mucosa of both the stomach and colon contribute to the complications of acromegaly.
A. A. Titaeva   +4 more
doaj   +1 more source

Tumor‐infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy

open access: yesJournal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Abstract Tumor‐infiltrating immune cells (TICs) are important components of the tumor microenvironment (TME). They regulate somatotroph adenoma treatment responses to therapy with somatostatin receptor ligands (SRLs), mediated by soluble factors and cytokines. In this study, we assessed the effect of SRLs treatment on TICs.
Sabrina Chiloiro   +16 more
wiley   +1 more source

Petrified ears due to auricular ossification: an underreported clinical sign in acromegaly [PDF]

open access: bronze, 2022
Avivar Awasthi   +3 more
openalex   +1 more source

Reversible Vision Loss With Pituitary Microadenoma Following PRP Injection for Hair Growth: A Rare Case Report and a Mini‐Review of the Literature

open access: yesClinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Platelet‐rich plasma (PRP) therapy, while widely utilized for its favorable safety profile, carries a recognized risk of catastrophic, irreversible vision loss, traditionally attributed to iatrogenic vascular embolization following facial injections.
Fazeela Bibi   +6 more
wiley   +1 more source

Myocardial, Valvular, and Vascular Structural and Functional Properties in Acromegaly [PDF]

open access: gold, 2023
Attila Nemes   +4 more
openalex   +1 more source

Expression of microRNA related to bone remodeling regulation in plasma in patients with acromegaly

open access: yesОжирение и метаболизм, 2017
Backgraund. MiсroRNA are small regulatory factors that regulate gene expression by post-transcriptional regulation of mRNA, playing an important role in numerous cellular processes including organogenesis, apoptosis, cell proliferation and ...
Tatiana A. Grebennikova   +6 more
doaj   +1 more source

Acromegaly and Osteoarthritis: a retrospective study of joint involvement in the spine, thorax, and shoulder complex

open access: yesОжирение и метаболизм
BACKGROUND: Acromegaly is a severe neuroendocrine disorder caused by growth hormone hypersecretion, leading to various organ-system complications. In acromegaly, radiographic signs of osteoarthritis (OA) involving multiple joints develop even before the ...
M. A. Perepelova   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy